Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB

European Journal of Pharmacology

Volumn 631, Issue 1-3, 2010, Pages 1-9

  Kim, Sun Mi ^a,b   Lee, So Yong ^a   Cho, Jin Suk ^a   Son, Seung Mo ^a   Choi, Sang Sook ^b   Yun, Yeo Pyo ^a   Yoo, Hwan Soo ^a   Yoon, Do Young ^c   Oh, Ki Wan ^a   Han, Sang Bae ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

Apoptotic cell death; NF B; Prostate cancer; Rg3

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DOCETAXEL; DOXORUBICIN; GINSENOSIDE RG 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; GENE EXPRESSION; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; CISPLATIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; GINSENOSIDES; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS;

EID: 76549121864     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.018     Document Type: Article

References (58)

1. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., Afaq F., Pasha F.S., Saleem M., and Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 1 13 (2007) 1611-1619
2. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 60 (2000) 1051-1059
3. Amer A.B., and Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science 274 (1996) 782-784
4. Andrzejewski T., Deeb D., Gao X., Danyluk A., Arbab A.S., Dulchavsky S.A., and Gautam S.C. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res. 17 (2008) 257-267
5. Anil T.K., Singh R.P., Agarwal C., Chan D.C.F., and Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res. 8 (2002) 3512-3519
6. Banerjee S., Hussain M., Wang Z., Saliganan A., Che M., Bonfil D., Cher M., and Sarkar F.H. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67 (2007) 3818-3826
7. Ban J.O., Lee H.S., Jeong H.S., Song S., Hwang B.Y., Moon D.C., Yoon do Y., Han S.B., and Hong J.T. Thiacremonone augments chemotherapeutic agent-induced growth inhibition in human colon cancer cells through inactivation of nuclear factor-{κ}B. Mol. Cancer Res. 7 6 (2009) 870-879
8. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C., and Dörken B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100 (1997) 2961-2969
9. Barkett M., and Gilmore T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18 (1999) 6910-6924
10. Chen Y.H., Lin S.J., Chen J.W., Ku H.H., and Chen Y.L. Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits. Br. J. Pharmacol. 135 (2002) 37-47
11. Chuang S.E., Yeh P.Y., and Lu Y.S. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol. 63 (2002) 1709-1716
12. Cortes J.E., and Pazdur R. Docetaxel. J. Clin. Oncol. 13 (1995) 2643-2655
13. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncol.Rev. (2004) 282-294
14. Dong Q.G., Sclabas G.M., and Fujioka S. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21 (2002) 6510-6519
15. El-Rayes B.F., Ali S., Ali I.F., Philip P.A., Abbruzzese J., and Sarkar F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 66 (2006) 10553-10559
16. Ferraresi V., Milella M., Vaccaro A., D'Ottavio A.M., Papaldo P., Nisticò C., Thorel M.F., Marsella A., Carpino A., Giannarelli D., Terzoli E., and Cognetti F. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am. J. Clin. Oncol. (2000) 132-139
17. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., Kalman L., Miller V., Lee J.S., Moore M., Gandara D., Karp D., Vokes E., Kris M., Kim Y., Gamza F., and Hammershaimb L. 2004. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18 (2000) 2354-2362
18. Garg A., and Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16 (2002) 1053-1068
19. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., and Piwnica-Worms H. The chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275 (2000) 5600-5605
20. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., and Egan L.J. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
21. Hong W.K., and Sporn M.B. Recent advances in chemoprevention of cancer. Science 278 (1997) 1073-1077
22. Huang Y., Johnson K.R., Norris J.S., and Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 60 (2000) 4426-4432
23. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics. CA Cancer J. Clin. 52 (2002) 23-47
24. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., and Green D.R. DNA damaging agents induce expression of Fas Ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell. 1 4 (1998) 543-551
25. Kelloff G.J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78 (2000) 199-334
26. Keum Y.S., Han S.S., Chun K.S., Park K.K., Park J.H., Lee S.K., and Surh Y.J. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat. Res. 523-524 (2003) 75-85
27. Kim W.Y., Kim J.M., Han S.B., Lee S.K., Kim N.D., Park M.K., and Park J.H. Steaming of ginseng at high temperature enhances biological activity. J. Nat. Prod. 63 (2000) 1702-1704
28. Kim J.H., Xu C., Keum Y.S., Reddy B., Conney A., and Kong A.N. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27 (2006) 475-482
29. Lee S.Y., Yuk D.Y., Song H.S., Yoon d.Y., Jung J.K., Moon D.C., Lee B.S., and Hong J.T. Growth inhibitory effects of obovatol through induction of apoptopic cell death in prostate and colon cancer by blocking of NF-κB. Eur. J. Pharmacol. 582 1-3 (2008) 17-25
30. Lin Z.P., Boller Y.C., Amer S.M., Russell R.L., Pacelli K.A., Patierno S.R., and Kennedy K.A. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-κB activation in drug resistance. Cancer Res. 58 (1998) 3059-3065
31. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Kawagoe J., Takahashi K., Yada-Hashimoto N., Seino-Noda H., Sakata M., Motoyama T., Kurachi H., Testa J.R., Tasaka K., and Murata Y. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 15 (2004) 7645-7654
32. Millikan R., Baez L., Banerjee T., Wade J., Edwards K., Winn R., Smith T.L., and Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol. Oncol. 6 (2001) 111-115
33. Okada S., Sakata Y., Matsuno S., Kurihara M., Sasaki Y., Ohashi Y., and Taguchi T. Br. J. Cancer. 80 (1999) 438-443
34. Oyaizu H., Adachi Y., and Okumura T. Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol. Rep. 8 (2001) 825-829
35. Pares A., Planas R., Torres M., Caballeria J., Viver J.M., Acero D., Panes J., Rigau J., Santos J., and Rodes J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. 28 (1998) 615-621
36. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., and Price B.D. Constitutive activation of Ikappa B alpha and NF-kappB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18 (1999) 7389-7394
37. Perkins N.D. The Rel/NF-κB family: friend and foe. Trends Biochem. Sci. 25 (2000) 434-440
38. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. Nature 431 (2004) 461
39. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., and Kasem S. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
40. Qadan L.R., Perez-Stable C.M., Anderson C., D'Ippolito G., Herron A., Howard G.A., and Roos B.A. 2-Methoxyestradiol induces G2-M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285 (2001) 1259-1266
41. Ryan D.P., Kulke M.H., Fuchs C.S., Grossbard M.L., Grossman S.R., Morgan J.A., Earle C.C., Shivdasani R., Kim H., Mayer R.J., and Clark J.W. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 1 94 (2002) 97-103
42. Scifo C., Milasi A., Guarnera A., Sinatra F., and Renis M. Resveratrol and propolis extract: an insight into the morphological and molecular changes induced in DU145 cells. Oncol. Res. 15 (2006) 409-421
43. Shaikh I.A., Brown I., Schofield A.C., Wahle K.W., and Heys S.D. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68 (2008) 1635-1646
44. Shirley R.B., Kaddour-Djebbar I., Patel D.M., Lakshmikanthan V., Lewis R.W., and Kumar M.V. Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells. Neoplasia 7 (2005) 1104-1111
45. Shigemura K., Arbiser J.L., Sun S.Y., Zayzafoon M., Johnstone P.A., Fujisawa M., Gotoh A., Weksler B., Zhau H.E., and Chung L.W. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109 (2007) 1279-1289
46. Singh R.P., Tyagi A.K., Zhao J., and Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis. Lond. 23 (2002) 499-510
47. Sporn M.B., and Suh N. Chemoprevention of cancer. Carcinogenesis. Lond. 21 (2000) 525-530
48. Suh J., and Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon. J. Cell. Biochem. 291 (2004) 100-117
49. Tedesco K.L., Thor A.D., Johnson D.H., Shyr Y., Blum K.A., Goldstein L.J., Gradishar W.J., Nicholson B.P., Merkel D.E., Murrey D., Edgerton S., and Sledge G.W. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J. Clin. Oncol. 15 22 (2004) 1071-1077
50. Uzzo R.G., Leavis P., and Hatch W. Zinc inhibits nuclear factorkappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. 8 (2002) 3579-3583
51. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., and Verma I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274 (1996) 787-789
52. Waddick K.G., and Uckun F.M. Innovative treatment programs against cancer: II. Nuclear factor-κB (NF-κB) as a molecular target. Biochem. Pharmacol. 57 (1999) 9-17
53. Wang C.Y., Cusack J.C., Liu R., and Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 5 (1999) 412-417
54. Wang C.Y., Mayo M.W., and Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
55. Weldon C.B., Burow M.E., Rolfe K.W., Clayton J.L., Jaffe B.M., and Beckman B.S. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 130 (2001) 143-150
56. Xie X., Eberding A., Madera C., Fazli L., Jia W., Goldenberg L., and Gleave M. Guns ES.Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J. Urol. 175 (2006) 1926-1931
57. Yance D.R., and Sagar S.M. Targeting angiogenesis with integrative cancer therapies. Integr. Cancer Ther. Rev. 5 (2006) 9-29
58. Zhang H., Morisaki T., and Nakahara C. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22 (2003) 2088-2096